Here's a short "guff" post to start the month of December...
Pioglitazone is a drug indicated in multiple
clinical settings as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
A recent US FDA safety review suggests
that use of pioglitazone for more than 12 months is associated with an
increased risk for bladder cancer. Observational studies and a review by
the European Medicines Agency (EMA) have supported this conclusion.
The labels have now been updated to state that pioglitazone should not be started in patients with active
bladder cancer and should be used with caution in patients with a prior
history of bladder cancer.
Further, the new labels state that patients should contact their
doctors if they either experience blood or see a red color in their
urine. Patients should also be aware of other symptoms that might be due
to bladder cancer, including new or worsening urinary urgency or pain
on urination since starting pioglitazone.
Source: FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines
Click HERE to subscribe to Know Guff by email